{
    "clinical_study": {
        "@rank": "105815", 
        "arm_group": [
            {
                "arm_group_label": "olodaterol 2 mcg", 
                "arm_group_type": "Experimental", 
                "description": "solution for inhalation"
            }, 
            {
                "arm_group_label": "olodaterol 5 mcg", 
                "arm_group_type": "Experimental", 
                "description": "solution for inhalation"
            }, 
            {
                "arm_group_label": "olodaterol 10 mcg", 
                "arm_group_type": "Experimental", 
                "description": "solution for inhalation"
            }, 
            {
                "arm_group_label": "olodaterol 20 mcg", 
                "arm_group_type": "Experimental", 
                "description": "solution for inhalation"
            }, 
            {
                "arm_group_label": "olodaterol 40 mcg", 
                "arm_group_type": "Experimental", 
                "description": "solution for inhalation"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "solution for inhalation"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective: To investigate bronchodilator effect and safety of single doses of BI\n      1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics\n      of BI 1744 CL"
        }, 
        "brief_title": "Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease", 
        "completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Diagnosis of chronic obstructive pulmonary disease\n\n          2. Smoking history of more than 10-pack years\n\n        Exclusion criteria:\n\n          1. History of asthma, allergic rhinitis, myocardial infarction or unstable of\n             life-threatening cardiac arrhythmias\n\n          2. Marked baseline prolongation of QT/QTc interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809262", 
            "org_study_id": "1222.3"
        }, 
        "intervention": [
            {
                "arm_group_label": "olodaterol 5 mcg", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of 5 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "olodaterol 40 mcg", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of 40 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "olodaterol 20 mcg", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of 20 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "olodaterol 2 mcg", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of 2 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "olodaterol 10 mcg", 
                "description": "solution for inhalation", 
                "intervention_name": "single dose of 10 mcg", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "March 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Heerlen", 
                    "country": "Netherlands"
                }, 
                "name": "1222.3.1 Atrium medisch centrum"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "6", 
        "official_title": "Single Dose Preliminary Dose-ranging and Safety in Patients With COPD", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Forced expiratory volume in one second (FEV1) at 24 hours after a single dose", 
            "safety_issue": "No", 
            "time_frame": "at 24 h post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Peak FEV1 after a single dose", 
                "safety_issue": "No", 
                "time_frame": "up to 3 h post-dose"
            }, 
            {
                "measure": "Area under the FEV1 curve till 12 h (FEV1 AUC0-12) after a single dose", 
                "safety_issue": "No", 
                "time_frame": "baseline till 12 h post-dose"
            }, 
            {
                "measure": "FEV1 AUC0-24h after a single dose", 
                "safety_issue": "No", 
                "time_frame": "baseline till 24 h post-dose"
            }, 
            {
                "measure": "FEV1 AUC12-24h after a single dose", 
                "safety_issue": "No", 
                "time_frame": "from 12 h till 24 h post-dose"
            }, 
            {
                "measure": "FEV1 AUC0-3h after a single dose", 
                "safety_issue": "No", 
                "time_frame": "baseline till 3 h post-dose"
            }, 
            {
                "measure": "Peak forced vital capacity (FVC) after a single dose", 
                "safety_issue": "No", 
                "time_frame": "up to 3 h post-dose"
            }, 
            {
                "measure": "Time to peak bronchodilator response after a single dose", 
                "safety_issue": "No", 
                "time_frame": "up to 3 h post-dose"
            }, 
            {
                "measure": "Time to onset of response after a single dose", 
                "safety_issue": "No", 
                "time_frame": "up to 24 h post-dose"
            }, 
            {
                "measure": "Number of patients requiring rescue medication on a test-day after a single dose", 
                "safety_issue": "No", 
                "time_frame": "up to 24 h post-dose"
            }, 
            {
                "measure": "Adverse events: during study period onset and end date, causality and intensity of any untoward medical occurrence were recorded", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks"
            }, 
            {
                "measure": "Vital signs: blood pressure and heart rate on test-days in conjunction with each lung function test, and at screening and at completion of last test-day (or at withdrawal visit)", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks"
            }, 
            {
                "measure": "12-lead ECGs: at screening and at completion of last test-day (or at withdrawal visit)", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks"
            }, 
            {
                "measure": "Laboratory evaluations (routine blood chemistry, haematology and urinalysis): at screening and at completion of last test-day (or at withdrawal visit)", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}